x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAA-001254
| Product Information | |
|---|---|
| Product Name | Phospho-PI 3 kinase p85 + Total In-Cell ELISA Kit (Chemiluminescent) |
| Species | Human; Mouse; Rat |
| Description | Phospho-PI3 kinase p85 + Total In-Cell ELISA Kit (Chemiluminescent) provides a simple, efficient, cell-based method to monitor proteins activated by phosphorylation. The kit is designed specifically to quantify activated (phosphorylated) phosphoinositide 3 Kinase (PI3K) p85 and/or total PI 3 Kinase p85. Cells are cultured in 96-well plates and stimulated to induce the pathway of interest. Following stimulation, the cells are rapidly fixed to preserve activation-specific protein modifications. Each well is then incubated with a primary antibody that recognizes either phosphorylated PI 3 Kinase p85 or total PI 3 Kinase p85. Subsequent incubation with secondary HRP-conjugated antibody and developing solution provides an easily quantified chemiluminescent readout. The relative number of cells in each well is then determined using the provided Crystal Violet solution. The 96-well plate format is suitable for high-throughput screening applications. The Phospho-PI3 kinase p85 + Total In-Cell ELISA Kit (Chemiluminescent) contains two 96-well plates and two primary antibodies. The phospho-PI3 kinase p85 antibody recognizes peptides and proteins containing p85 PI3-Kinase phospho-tyrosine 467 (alpha) or 199 (gamma). No cross-reactivity is observed with corresponding non-phosphorylated sequences or with other phospho-tyrosine-containing motifs. The total-PI 3 Kinase p85 antibody recognizes the total level of PI 3 Kinase p85 proteins regardless of the phosphorylation state. The kit can be used to study phosphorylated PI 3 Kinase relative to cell number or to determine PI 3 Kinase phosphorylation relative to the total PI 3 Kinase protein found in the cells. Once the phospho-PI 3 Kinase and total-PI 3 Kinase signals have been normalized for cell number, a comparison of the ratio of phosphorylated PI 3 Kinase to total PI 3 Kinase for each of the cell growth conditions can be made. The provided total-PI 3 Kinase antibody can be used as a positive control to demonstrate that the cells contain PI 3 Kinase, the kit reagents are functional and that the protocol is performed correctly. |
| Sample Types | Adherent Cells, Suspension Cells |
| Target Information | |
|---|---|
| Target Name | PIK3R1 |
| UniProt No. | P27986 |
| Gene ID | 5295 |
| Target Description | Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. |
| Alternative Names | GRB1; p85; p85 alpha; P85A_HUMAN; Phosphatidylinositol 3 kinase associated p 85 alpha; Phosphatidylinositol 3 kinase regulatory 1; Phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 1 (p85 alpha); Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; Phosphatidylinositol 3-kinase regulatory subunit alpha; Phosphoinositide 3 kinase, regulatory subunit 1 (alpha); PI3 kinase p85; PI3 kinase p85 subunit alpha; PI3-kinase regulatory subunit alpha; PI3-kinase subunit p85-alpha; PI3K; PI3K p85; PI3K regulatory subunit alpha; Pik3r1; PtdIns 3 kinase p85 alpha; PtdIns-3-kinase regulatory subunit alpha; PtdIns-3-kinase regulatory subunit p85-alpha |
| Shipping & Storage | |
|---|---|
| Sipping | Shipping on dry ice. |
| Storage | Store at -20°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
